SCHLIEREN, Switzerland, LAUSANNE, Switzerland and SAN DIEGO, Oct. 6 Oncalis AG (Oncalis), a privately-owned Swiss biotechnologycompany, and ChemDiv Inc. (ChemDiv), a privately-owned, California-baseddiscovery services company announced that they entered into an exclusiveagreement for a license to Oncalis a family of PI3K inhibitors. ONC-201, thefirst development candidate from this family, is a potent and selectiveorally-bioavailable member of a new class of drugs targeting PI3-kinase.ONC-201 has demonstrated highly promising anti-cancer efficacy in pre-clinicalcancer models.
Under the terms of the agreement, Oncalis receives a family of compoundstargeting different forms of PI3-kinase (PI3-K). PI3-K is an enzyme known tobe important in cancer disease progression and potentially in the regulationof certain immune and inflammation-related diseases. The potential of PI3-Kinhibitors has been recently confirmed by advancing development programs fromtop-tier pharmaceutical companies with this class of compounds. Under theterms of the agreement ChemDiv will perform R&D activities for Oncalis' leadcompounds. Financial terms of the agreement were not disclosed.
Commenting on the license, Dr. Didier Coquoz, CEO, and Dr. AlcideBarberis, CSO/COO, said that "the in-licensing of the PI3-kinase programrepresents a major evolution for Oncalis, a company dedicated to thedevelopment of oral inhibitors of kinases for the treatment of cancer. Thisprogram expands Oncalis' internal portfolio and we are extremely excited tosuccessfully move ahead with the development of the PI3-kinase inhibitor ONC-201 in addition to the triple RAF/EGFR/EPHB4 inhibitor ONC-101. We aim toenter clinical trials within the next two years with very promising newanticancer drugs in an extremely promising segment of oncology treatment".
"ChemDiv successfully provided research services to Oncalis over the pasttwo years. We are excited about this new collaboration with our establishedpartner. I am pleased that Oncalis shares our enthusiasm for the therapeuticpotential of PI3-kinase inhibitors and ONC-201 in particular for multiplecancer indications," said Dr. Nikolay Savchuk, President and CEO of ChemDiv."Oncalis has a significant development and business expertise in oncologywhich we believe will help accelerate the development of these novel smallmolecules designed to inhibit the important cancer and inflammation relatedPI3K-Akt pathway."
Oncalis AG is a drug development company based in Schlieren near Zurich,Switzerland supported by VI Partners, Zurcher KantonalBank and privateinvestors. Oncalis business model is focused around its core expertise inkinase inhibitors and drug development within the highly rewarding developmentsteps from early preclinical to initial clinical proof-of-concept. Oncalis isoperating in a virtual mode using a highly experimented internal team as wellas top-tier experts and sub-contractors.
ChemDiv Inc. (Chemical Diversity) is a global chemistry-driven contractresearch organization accelerating discovery and development of noveltherapies through comprehensive Discovery outSource(TM) services, includingpre-clinical development, discovery biology, medicinal and syntheticchemistry.
SOURCE ChemDiv Inc.; Oncalis AG